SN-38
- Generic Name
- SN-38
- Brand Names
- Trodelvy
- Drug Type
- Small Molecule
- Chemical Formula
- C22H20N2O5
- CAS Number
- 86639-52-3
- Unique Ingredient Identifier
- 0H43101T0J
- Background
7-ethyl-10-hydroxycamptothecin (SN 38) is a liposomal formulation of the active metabolite of Irinotecan Irinotecan, a chemotherapeutic pro-drug approved for the treatment of advanced colorectal cancer. SN 38 has been used in trials studying the treatment of Cancer, Advanced Solid Tumors, Small Cell Lung Cancer, Metastatic Colorectal Cancer, and Triple Negat...
- Indication
Investigated for use/treatment in colorectal cancer.
- Associated Conditions
- Hormone Receptor Positive Metastatic Breast Cancer, Locally Advanced or Metastatic Urothelial Carcinoma (UC), Metastatic Triple Negative Breast Cancers, Unresectable Triple-Negative Breast Carcinoma, Metastatic HR Positive, HER2/Neu Negative Breast Cancer, Unresectable Locally Advanced Triple-negative Breast Cancer, Unresectable, locally advanced HR Positive, HER2/Neu Negative Breast Cancer, Unresectable, locally advanced Hormone Receptor Positive Breast Carcinoma
- Associated Therapies
- -
Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 18
- Registration Number
- NCT05143229
- Locations
- 🇺🇸
The University of Kansas Cancer Center - Overland Park, Overland Park, Kansas, United States
🇺🇸The University of Kansas Cancer Center - Indian Creek, Overland Park, Kansas, United States
🇺🇸The University of Kansas Clinical Research Center, Fairway, Kansas, United States
Study of Sacituzumab Govitecan in Patients With Solid Tumor
- First Posted Date
- 2021-11-15
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 300
- Registration Number
- NCT05119907
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, China
🇨🇳Chinese Academy of Medical Sciences Cancer Hospital, Beijing, China
🇨🇳Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China
Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- G1 Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05113966
- Locations
- 🇺🇸
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
🇺🇸Rocky Mountain Cancer Centers, Denver, Colorado, United States
Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 143
- Registration Number
- NCT05101096
- Locations
- 🇯🇵
Kagawa University Hospital, Kagawa, Japan
🇯🇵Aichi Cancer Center Hospital, Aichi, Japan
🇯🇵Akita University Hospital, Akita, Japan
Strata PATH™ (Precision Indications for Approved Therapies)
- Conditions
- Interventions
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Strata Oncology
- Target Recruit Count
- 700
- Registration Number
- NCT05097599
- Locations
- 🇺🇸
Kettering Health Network, Kettering, Ohio, United States
🇺🇸Florida Cancer Specialists - Panhandle, Tallahassee, Florida, United States
🇺🇸Florida Cancer Specialists - North, Saint Petersburg, Florida, United States
P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .
- Conditions
- Interventions
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Veru Inc.
- Registration Number
- NCT05008510
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 195
- Registration Number
- NCT05006794
- Locations
- 🇺🇸
Novant Health Cancer Institute - Elizabeth (Breast Cancer), Charlotte, North Carolina, United States
🇮🇱Rambam Health Care Campus, Haifa, Israel
🇮🇱Hadassah Medical Center- Ein Kerem, Jerusalem, Israel
Scalp Cooling in MBC
- Conditions
- Interventions
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 120
- Registration Number
- NCT04986579
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 92
- Registration Number
- NCT04958785
- Locations
- 🇦🇺
St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
🇺🇸Charleston Oncology, Charleston, South Carolina, United States
🇦🇺Peninsula Health, Frankston, Victoria, Australia
A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies
- Conditions
- Interventions
- First Posted Date
- 2021-06-16
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT04927884
- Locations
- 🇺🇸
Hoag Memorial Hospital, Newport Beach, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.